Axovant to Present New Results on Intepirdine and Nelotanserin Research Programs

Axovant to Present New Results on Intepirdine and Nelotanserin Research Programs
New results from its intepirdine (RVT-101) and nelotanserin research programs on Alzheimer’s disease (AD) and Lewy body dementia will be shared soon, Axovant Sciences announced. The data will be presented at the 2017 Alzheimer’s Association International Conference (AAIC) in London  July 16-20. Intepirdine is a selective antagonist of the 5HT6 receptor. This effect leads to the release

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *